The SAPIT study [14] determined that antiretroviral treatment should be started during the intensive phase or maintenance phase of tuberculosis treatment in patients with pulmonary TB and should not be delayed until after the completion of the latter, at least for patients with CD4+ T-cells counts equal to or lower than 500 cells/μL. This evidence concerns the gene CD4 and pulmonary tuberculosis.